Sort   by:  
 Page size 
UnknownA placebo-controlled, blinded and randomised study on the effects of recombinant human thyrotropin on quality of life in the treatment of thyroid cancer.
Not available
S-EPMC4017756 | biostudies-literature
UnknownDepletion of T lymphocytes is correlated with response to temozolomide in melanoma patients.
Not available
S-EPMC3601183 | biostudies-literature
UnknownImpact of patient-reported outcomes on symptom monitoring during treatment with checkpoint inhibitors: health-related quality of life among melanoma patients in a randomized controlled trial.
Not available
S-EPMC8782960 | biostudies-literature
UnknownImproved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma.
Not available
S-EPMC7564087 | biostudies-literature
UnknownThe use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial.
Not available
S-EPMC7599285 | biostudies-literature
UnknownCardiotoxicity in patients with metastatic melanoma treated with BRAF/MEK inhibitors: a real-world analysis of incidence, risk factors, and reversibility.
Not available
S-EPMC12012651 | biostudies-literature
UnknownLong-term clinical outcome of patients with metastatic melanoma and initial stable disease during anti-PD-1 checkpoint inhibitor immunotherapy with pembrolizumab.
Not available
S-EPMC12322104 | biostudies-literature
UnknownEffect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer.
Not available
S-EPMC5091223 | biostudies-literature
UnknownA prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.
Not available
S-EPMC3239318 | biostudies-literature
UnknownReal-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma.
Not available
S-EPMC6826482 | biostudies-literature
Sort   by:  
 Page size